| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |